Yuhan Corp. has secured an 84.9 billion won ($64.5 million) contract to supply hepatitis C treatment APIs to Gilead Sciences, representing 4.11% of its annual sales, with deliveries set from May 2026 to May 2027.
#YonhapInfomax #YuhanCorp #GileadSciences #HepatitisCTreatment #APISupply #849BillionWon #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=78889
#GileadSciences
Yuhan Corp. has secured an 84.3 billion won ($63.5 million) API supply contract with Gilead Sciences for HIV treatments, representing 4.08% of its annual sales.
#YonhapInfomax #YuhanCorp #GileadSciences #APISupply #HIVTreatment #843BillionWon #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=77789
Tamar Braxton Teams Up With Gilead To Educate Black Women On HIV Prevention & PrEP Usage https://shinemycrown.com/tamar-braxton-teams-up-with-gilead-to-educate-black-women-on-hiv-prevention-prep-usage/?utm_source=dlvr.it&utm_medium=mastodon #TamarBraxton #HIVPrevention #BlackWomen #PrEP #GileadSciences
Yuhan Corporation secures 88.8 billion won contract with Gilead Sciences for additional supply of HIV treatment API, expanding on previous 107.7 billion won deal
#YonhapInfomax #YuhanCorporation #GileadSciences #HIVTreatment #APISupply #PharmaceuticalContract #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64398
Gilead Sciences announces $11 billion additional investment in US amid tariff pressure, aiming to boost domestic manufacturing and R&D capabilities by 2030
#YonhapInfomax #GileadSciences #USInvestment #PharmaceuticalIndustry #TariffPolicies #DomesticProduction #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62277
Gilead: #HIVMedikamente für alle zugänglich und bezahlbar machen.
Das HIV-Medikament #Lenacapavir von #GileadSciences könnte laut einer Untersuchung nur 37 Euro pro Behandlung kosten. #Gilead verlangt jedoch mehr als 37.000 Euro dafür.
Das Medikament könnte lebensrettend sein. Statt täglich Tabletten einzunehmen, wäre nur noch alle 6 Monate eine Spritze nötig.
Doch dafür muss Gilead aufhören, seine Profite über Menschenleben zu stellen.
Petition hier unterzeichnen: https://action.eko.org/a/gilead-medikamente-bezahlbar-machen
1/ "Das #HIV-#Medikament #Lenacapavir von #GileadSciences könnte laut einer Untersuchung nur 37 Euro pro Behandlung kosten. Gilead verlangt jedoch mehr als 37.000 Euro dafür."
✍🏻 Gilead:
HIV-Medikamente für alle zugänglich und bezahlbar machen!
https://action.eko.org/a/gilead-medikamente-bezahlbar-machen
https://healthnews.pt/.../10a-edicao-programa-gilead.../
A Gilead Sciences anuncia que o prazo para submissão de candidaturas à 10ª edição do Programa Gilead GÉNESE, foi prorrogado até ao próximo dia 30 de setembro de 2024.
#HealthNews #saude #GileadSciences
HIV prevention drug found 100% effective in clinical trial
https://www.livescience.com/health/hiv/hiv-prevention-drug-found-100-effective-in-clinical-trial
#health #HIV #prevention #ClinicalTrial #lenacapavir #prophylaxis #PrEP #GileadSciences
US government appeals Gilead's trial win in Truvada, Descovy patent fight—Lilly’s Mounjaro helps patients lose more weight than Novo’s Ozempic — FTC report finds PBM power has “dire consequences” —http://bit.ly/w28kSd #gileadsciences #patents #elililly #mounjaro #ozempic #novonordisk #ftc #pbms #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset—BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival —Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority—http://bit.ly/w28kSd #gileadsciences #cancer #antibodydrugconjufate #eisai #bristolmyerssquibb #supremecourt #fda #chevrondoctrine #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Gilead bets on Xilio cancer drug as biotech restructures—Sanders blasts Novo Nordisk for ‘outrageous’ price of Ozempic, Wegovy—Boundless Bio breaks IPO lull with $100M fundraise--http://bit.ly/w28kSd #gileadsciences #solidtumors #berniesanders #drugpricing #novonordisk #ozempic #wegovy #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Merck’s Keytruda pushes towards earlier stages of cervical cancer with phase III data—Gilead CAR-T cancer therapy capacity to quadruple by 2026—Madrigal wins FDA approval of first drug for MASH--http://bit.ly/w28kSd #merck #keytruda #cervicalcancer #clinicaltrials #cart #gileadsciences #fda #mash #nash #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Could pharma’s legal attack on the IRA succeed in killing price negotiations?—Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab—Sandoz nabs FDA approvals for first two biosimilars for Amgen’s denosumab--http://bit.ly/w28kSd #inflationreductionact #medicare #drugpricing #gileadsciences #sandoz #biosimilars #amgen #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Gilead pays $4.3B for CymaBay, primarily for liver disease med—Pharma showed up for the big game — CSL’s ‘big’ post-heart attack drug fails in Phase III trial--http://bit.ly/w28kSd #gileadsciences #mergersandacquisitions #liverdisease #heartattack #clinicaltrials #superbowl #pharmaadvertising #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Eisai, Biogen likely to miss early launch goal for Alzheimer's drug Leqembi—J&J could face class action for allegedly mismanaging employee health plan — Gilead will not buy Tizona after paying $300M for the right to do so--http://bit.ly/w28kSd #eisai #biogen #alzheimers #jnj #employeebenefits #legal #gileadsciences #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
6 neuro data readouts to watch in the first half of 2024 —Gilead's Trodelvy fails to extend survival in lung cancer study — Next stage in GSK’s Zantac defense gets underway today --http://bit.ly/w28kSd #neurodegenerativedisease #gileadsciences #clinicaltrials #lungcancer #legal #gsk #zantac #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
📬 Filmemacher machte Millionen mit riskanten Dogecoin-Investments
#Krypto #Kurios #CarlErikRinsch #Dogecoin #GabrielaRosésBentancor #GileadSciences #netflix #RollsRoyce #VacheronConstantin https://tarnkappe.info/artikel/krypto/filmemacher-machte-millionen-mit-riskanten-dogecoin-investments-283913.html
As Biogen's sales flatline, CEO Chris Viehbacher touts progress on Leqembi, Skyclarys and other launches-- Bayer CEO Anderson says 'radical realignment' is underway --Gilead tumbles after unpredictable element drove its 3Q beat -- See more on our front page news http://bit.ly/w28kSd #biogen #pharmaceos #bayer #layoffs #gileadsciences #earnings #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Can we end AIDS as a public health threat by 2030? Key groups are still left behind and account for an estimated 65% of new HIV infections. In Sub Saharan Africa, 85% of new HIV infections are in young people aged 15-19. But innovation may make the 2030 goal real. I’m chairing a #whs2023 panel supported by #GileadSciences with Florence Riako Anam of GNP+, Janet Dorling of Gilead, Christine Stegling of UNAIDS, Dr Mamadi Yilla of PEPFAR. 10.00 GMT , 17 Oct https://youtube.com/live/JzxsmT4Ph6Y
Client Info
Server: https://mastodon.social
Version: 2025.07
Repository: https://github.com/cyevgeniy/lmst